SVRA / Savara Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 SAVARA INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 SAVARA INC.

Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by

EX-99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases September 2025 © Savara Inc. All Rights Reserved. Exhibit 99.1 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2025 SAVARA INC.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2025 SAVARA INC.

SAVARA RECEIVES REFUSAL TO FILE (RTF) LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE BIOLOGICS LICENSE APPLICATION (BLA) FOR MOLBREEVI* TO TREAT PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

EX-99.1 Exhibit 99.1 SAVARA RECEIVES REFUSAL TO FILE (RTF) LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE BIOLOGICS LICENSE APPLICATION (BLA) FOR MOLBREEVI* TO TREAT PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) LANGHORNE, Pa. — May 27, 2025 — Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory

Composite Amended and Restated Certificate of Incorporation, as amended, of the Registrant.

Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows. 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc

Loan and Security Agreement, dated March 26, 2025, between the Company and the lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent.

Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. Certain information contained in this exhibit has been redacted where indicated because disclosure of such information would constitute a clearly unwarranted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

Insider Trading and Disclosure Policy.

Exhibit 19.1 Savara Inc. Insider Trading and Disclosure Policy This Insider Trading and Disclosure Policy (this “Policy”) sets forth the policy of Savara Inc. (f/k/a Mast Therapeutics, Inc.) (the “Company”) regarding transactions by certain individuals and entities involving securities of the Company and, where applicable, the disclosure of such transactions. All references to the “Company” in thi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2025 SAVARA INC.

Amended and Restated Executive Employment Agreement, dated March 13, 2025, between Savara Inc. and Kathleen McCabe.

Exhibit 10.40 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of March 13, 2025 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Kathleen McCabe (“Executive”). This Agreement amends and restates and supersedes in its entirety the Amended and Restated Executive Employm

Executive Employment Agreement, dated August 24, 2023, between Savara Inc. and Anne Erickson.

Exhibit 10.39 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of August 1, 2023 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Anne Erickson (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Business Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in con

Master Services Agreement by and between Savara ApS and Selvita S.A., effective January 17, 2024.

Exhibit 10.41 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. MASTER SERVICES AGREEMENT This Master Service Agreement (the “Agreement”) is made effective as of 17.01.2024 (“Effective Date”), by and between: SELVITA S.A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc.

Executive Employment Agreement, dated October 15, 2024, between Savara Inc. and Braden Parker.

Exhibit 10.38 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of October 15, 2024 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Braden Parker (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Commercial Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2025 SAVARA INC. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2025 SAVARA INC.

SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HERCULES CAPITAL — Includes $30M at Close to Refinance Existing Debt Facility —

Exhibit 99.1 SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HERCULES CAPITAL — Includes $30M at Close to Refinance Existing Debt Facility — LANGHORNE, PA – March 26, 2025 – Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercule

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 JOINT FILING 2 p25-0485exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the ne

JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k)

EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi

JOINT FILING AGREEMENT

JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Savara Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2025 SAVARA INC.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 SAVARA INC.

Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,”

Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2025 © Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “pla

AGREEMENT

EX-99.A 2 d891757dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Savara Inc. Date: November 27, 2024 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. B

SVRA / Savara Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment

SC 13G 1 d891757dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 805111101 (CUSIP Number) November 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

SVRA / Savara Inc. / PRUDENTIAL FINANCIAL INC Passive Investment

SC 13G/A 1 finsavara.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: SAVARA INC Title of Class of Securities: Common Stock CUSIP Number: 805111101 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A

EX-10.3

Exhibit 10.3 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Non-Qualified Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Nonqualified Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [

EX-10.2

Exhibit 10.2 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Incentive Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Incentive Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of

EX-10.4

Exhibit 10.4 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Restricted Stock Unit award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of Gra

Form of Nonqualified Stock Option Award Agreement under the 2024 Omnibus Incentive Plan.

Exhibit 10.3 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Non-Qualified Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Nonqualified Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [

Form of Incentive Stock Option Award Agreement under the 2024 Omnibus Incentive Plan.

Exhibit 10.2 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Incentive Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Incentive Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of

SVRA / Savara Inc. / Adage Capital Management, L.P. - SAVARA INC. Passive Investment

SC 13G/A 1 p24-3026sc13ga.htm SAVARA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This Statement) Check the appropriate

Form of Restricted Stock Unit Award Agreement under the 2024 Omnibus Incentive Plan.

Exhibit 10.4 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Restricted Stock Unit award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of Gra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara

Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation.

Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows. 1.

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Savara Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the

SVRA / Savara Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 805111101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

SVRA / Savara Inc. / Farallon Capital Partners, L.P. Passive Investment

SC 13G/A 1 savara13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) * Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (Cusip Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to

Savara Inc. 2021 Inducement Equity Incentive Plan, as amended

Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through September 17, 2024) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the

As filed with the Securities and Exchange Commission on October 1, 2024

As filed with the Securities and Exchange Commission on October 1, 2024 Registration No.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount  Registered(1)  Proposed  Maximum  Aggregate  Offering  Price Per  Unit  Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par

SVRA / Savara Inc. / Growth Equity Opportunities 17, LLC - GROWTH EQUITY OPPORTUNITIES 17, LLC / SAVARA INC -- 13D/A(#2) Activist Investment

SC 13D/A 1 geo17-savara18865.htm GROWTH EQUITY OPPORTUNITIES 17, LLC / SAVARA INC - 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Stephanie Brecher New Enterprise Associates

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.

As filed with the Securities and Exchange Commission on July 26, 2024

As filed with the Securities and Exchange Commission on July 26, 2024 Registration No.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0

SVRA / Savara Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us8051111016070824.txt us8051111016070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

Underwriting Agreement, dated June 27, 2024, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein

Exhibit 1.1 26,246,720 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT June 27, 2024 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introductory. Savara Inc., a Delaware corporation (the “Co

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2024 SAVARA INC.

SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK LANGHORNE, Pa., June 28, 2024— Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts

26,246,720 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279274 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2024) 26,246,720 Shares of Common Stock We are offering 26,246,720 shares of our common stock, $0.001 par value per share, in this offering. Our common stock is traded on The Nasdaq Global Select Market under the symbol “SVRA.” On June 27, 2024, the last reported sales

SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3 CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3 CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) • Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2024 SAVARA INC. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2024 SAVARA INC.

Savara Inc. 2024 Omnibus Incentive Plan

EX-10.1 Exhibit 10.1 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN 1. PURPOSE OF THE PLAN. The purpose of the 2024 Omnibus Incentive Plan (the “Plan”) is to provide favorable opportunities for directors, officers, employees, consultants or advisors employed by or providing services to Savara Inc., a Delaware corporation (the “Company”) or any of its Subsidiaries, to acquire shares of common stock of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 SAV

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 SAVARA INC.

Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation

Exhibit 3.1 SAVARA INC. CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that: 1. The name of the Corporation is Savara Inc. 2. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the St

SAVARA, INC. 1717 Langhorne Newtown Road, Suite 303 Langhorne, PA 19047

SAVARA, INC. 1717 Langhorne Newtown Road, Suite 303 Langhorne, PA 19047 May 20, 2024 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC, 20549 Re: Savara, Inc. Acceleration Request Registration Statement on Form S-3 File No. 333-279274 Dear Sir/Madam: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”),

Master Services Agreement (the “Agreement”), dated February 13, 2024, by and between Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. and Savara Inc.

Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. (1) FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED (2) FUJIFILM DIOSYNTH BIOTECHNOLOGIES TEXAS, LLC (3) FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC. AND (4)

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) SAVARA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc

As filed with the Securities and Exchange Commission on May 9, 2024

Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

Entry into a Material Definitive Agreement, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2024 SAVARA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

SVRA / Savara Inc. / Bain Capital Life Sciences Fund II, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.

Clawback Policy

Exhibit 97 SAVARA INC. POLICY REGARDING THE MANDATORY RECOVERY OF COMPENSATION EFFECTIVE NOVEMBER 28, 2023 I. Applicability. This Policy Regarding the Mandatory Recovery of Compensation (the “Policy”) applies to any Incentive Compensation paid to Savara Inc.’s (the “Company”) Executive Officers. The Policy is intended to comply with and be interpreted in accordance with the requirements of Listing

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex

Amendment No. 2 to the Manufacture and Supply Agreement, dated December 13, 2023 entered into by and between Savara ApS GEMABIOTECH SAU

Exhibit 10.36 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. AMENDMENT No. 2 TO MANUFACTURE AND SUPPLY AGREEMENT This Amendment No. 2 to the Manufacture and Supply Agreement (“Amendment No. 2”), dated December 13, 2023 (

Savara Inc. 2021 Inducement Equity Incentive Plan, as amended

Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through February 2024) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Comp

Power of Attorney is contained on the signature page

As filed with the Securities and Exchange Commission on March 7, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 SAVARA INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 SAVARA INC.

SVRA / Savara Inc. / Zambon Spa - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) January 24, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

SVRA / Savara Inc. / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm246235d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the

SVRA / Savara Inc. / PRUDENTIAL FINANCIAL INC Passive Investment

SC 13G 1 sav.htm DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: SAVARA INC Title of Class of Securities: Common Stock CUSIP Number: 805111101 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3) SEC USE ONLY

SVRA / Savara Inc. / CAXTON CORP Passive Investment

SC 13G/A 1 d1096525013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

SVRA / Savara Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - SAVARA INC. Passive Investment

SC 13G/A 1 p24-0475sc13ga.htm SAVARA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate bo

SVRA / Savara Inc. / Farallon Capital Partners, L.P. Passive Investment

SC 13G/A 1 svra13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7) * Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2024 SAVARA INC.

Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,”

EX-99.1 Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2024 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2024 SAVARA INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2024 SAVARA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.

SVRA / Savara Inc / Growth Equity Opportunities 17, LLC - GROWTH EQUITY OPPORTUNITIES 17, LLC / SAVARA INC -- 13D/A(#1) Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name,

Joint Filing Agreement.

Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement.

SVRA / Savara Inc / TCG Crossover GP I, LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) July 17, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh

SVRA / Savara Inc / Bain Capital Life Sciences Fund II, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D

EX-99.H Exhibit H AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) joi

21,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257709 PROSPECTUS SUPPLEMENT (To Prospectus dated July 16, 2021) 21,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock We are offering 21,000,000 shares of our common stock, $0.001 par value per share, in this offering. We are also offering to certain of our existing large inv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2023 SAVARA INC. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2023 SAVARA INC.

Underwriting Agreement, dated July 12, 2023, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein

EX-1.1 Exhibit 1.1 21,000,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT July 12, 2023 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladi

SAVARA ANNOUNCES PRICING OF $80 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $80 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS LANGHORNE, Pennsylvania – July 13, 2023 – Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share

Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on July 13, 2023).

EX-4.1 Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: July 17, 2023 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the

As filed with the Securities and Exchange Commission on June 16, 2023

S-8 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No.

Savara Inc. 2021 Inducement Equity Incentive Plan, as amended

EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through June 8, 2023) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of th

Filing fee table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC.

© Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by

EX-99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases June 2023 Exhibit 99.1 © Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC.

First Amendment to Lease Agreement, dated February 28, 2023, between Savara Inc. and 1717 OSSRE, LLC. (Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q filed on May 15, 2023.)

Exhibit 10.2 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this “Amendment”) is made this 28th day of February, 2023 (the “Effective Date”), by and between 1717 OSSRE, LLC, a Pennsylvania limited liability company (“Landlord”), and SAVARA INC., a Delaware corporation (“Tenant”). BACKGROUND A. Landlord and Tenant entered into a certain written Agreement of Lease dated July 7, 2021 (the “O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc

Lease Agreement, dated July 7, 2021, between Savara Inc. and 1717 OSSRE, LLC. (Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q filed on May 15, 2023.)

LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”), effective as of the 7th day of July, 2021 (the “Effective Date”), is made by and between 1717 OSSRE, LLC, a Pennsylvania limited liability company (“Landlord”), and SAVARA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex

List of Subsidiaries (Incorporated by reference to Exhibit 21.1 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2023.

Exhibit 21.1 Savara Inc. List of Subsidiaries Name Ownership % Aravas Inc. 100% Savara ApS 100% Drugrecure A/S 100% Pharmaorigin A/S 100% SD Pharmaceuticals, Inc. 100% Aires Pharmaceuticals, Inc. 100%

First Amendment to Lease Agreement, dated October 26, 2022, between the Registrant and Overlook at Rob Roy Owner, LLC.

Exhibit 10.29 DocuSign Envelope ID: 8B2E51B6-69B8-42A7-9E84-016D2871D63E October 26, 2022 FIRST AMENDMENT TO LEASE AGREEMENT Re: Lease Agreement dated May 11, 2021, by and between Overlook at Rob Roy Owner, LLC, as Lessor, and Savara, Inc., as Lessee, consisting of approximately 2,260 rentable square feet of space locally known as Suite III- 201 at 6836 Bee Caves Road, Austin, Travis County, Texas

Savara Inc. Amended and Restated 2015 Omnibus Incentive Plan, as amended

EX-4.1 Exhibit 4.1 SAVARA INC. AMENDED AND RESTATED 2015 OMNIMBUS INCENTIVE PLAN (as amended by the Board through March 8, 2023, subject to stockholder approval) Savara Inc., a Delaware corporation (f/k/a Mast Therapeutics, Inc., the “Company”), hereby establishes the amended and restated 2015 Omnibus Incentive Plan (the “Plan”), effective as of the Effective Date. 1. PURPOSE OF THIS PLAN The purp

As filed with the Securities and Exchange Commission on March 30, 2023

S-8 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2023 SAVARA INC. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2023 SAVARA INC.

Filing fee table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc.

Amendment No. 1 to the Manufacture and Supply Agreement, dated December 7, 2022 entered into by and between Savara ApS and GEMABIOTECH SAU (Incorporated by reference to Exhibit 10.33 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2023.)

Exhibit 10.33 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. AMENDMENT No. 1 TO MANUFACTURE AND SUPPLY AGREEMENT This Amendment No. 1 to the Manufacture and Supply Agreement (“Amendment No. 1”), dated December 7, 2022 (“

Executive Employment Agreement, dated November 10, 2022, between Savara Inc. and Raymond D. Pratt, M.D. (Incorporated by reference to Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2023.)

Exhibit 10.34 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of November 10, 2022 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Raymond D. Pratt, M.D. (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Medical Officer pursuant to the terms of this Agreement. NOW, THEREF

Savara Inc. 2021 Inducement Equity Incentive Plan, as amended

EX-4.2 Exhibit 4.2 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through March 8, 2023) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of t

Amended and Restated Bylaws of Savara, Inc., dated March 28, 2023 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 30, 2023).

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SAVARA INC. (a Delaware corporation) March 28, 2023 ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Savara Inc. (the “corporation”) shall be fixed in the Certificate of Incorporation of the corporation. 1.2 OTHER OFFICES. The board of directors may at any time establish the principal office and any branch or subordinate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 SAVARA INC. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 SAVARA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 SAVARA INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 SAVARA INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2023 SAVARA INC.

SVRA / Savara Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm236584d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the a

Executive Employment Agreement, dated February 13, 2023, between Savara Inc. and Rob Lutz (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 13, 2023.)

Exhibit 10.1 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of February 13, 2023 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Rob Lutz (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Operating Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in consi

Savara Inc. 2021 Inducement Equity Incentive Plan (Incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-8 filed on January 20 2023.)

EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through December 13, 2022) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0

As filed with the Securities and Exchange Commission on January 20, 2023

S-8 As filed with the Securities and Exchange Commission on January 20, 2023 Registration No.

Amended and Restated Executive Employment Agreement, dated December 13, 2022, between Savara Inc. and David Lowrance (Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on December 15, 2022.)

Exhibit 10.2 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into as of December 13, 2022 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and David Lowrance (?Executive?). This Agreement amends and restates and supersedes in its entirety the Executive Employment Agreement dated

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 13, 2022 SAVARA INC.

Amended and Restated Executive Employment Agreement, dated December 13, 2022, between Savara Inc. and Matthew Pauls (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on December 15, 2022.)

Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into as of December 13, 2022 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and Matthew Pauls (?Executive?). This Agreement amends and restates and supersedes in its entirety the Amended and Restated Executive Employm

As filed with the Securities and Exchange Commission on November 21, 2022

S-8 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.

Savara Inc. 2021 Inducement Equity Incentive Plan, as amended

EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended September 1, 2021 and September 8, 2022) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent

Filing fee table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2022 SAVARA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2022 SAVARA INC.

Amended and Restated Loan and Security Agreement, dated April 21, 2022, between the Registrant and its subsidiary, Aravas Inc., as borrowers, and Silicon Valley Bank (Incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q filed on May 11, 2022.)

Exhibit 10.1 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrower listed on Schedule I hereto (?Borrower?), and provides the terms on which Bank shall lend to Borrower, and Borrower shall repay Bank. This Agreement a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 21, 2022 SAVARA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex

Power of Attorney is contained on the signature page.

As filed with the Securities and Exchange Commission on March 30, 2022 Registration No.

Form of Restricted Stock Unit Agreement (Inducement Award) – Under the 2021 Inducement Equity Incentive Plan (Incorporated by reference to Exhibit 10.17 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2022.)

Exhibit 10.17 SAVARA INC. RESTRICTED STOCK UNIT AGREEMENT (INDUCEMENT AWARD) NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Awardee has been granted an award of Restricted Stock Units (the ?Award?) pursuant to this Agreement and the Savara Inc. 2021 Inducement Equity Plan (the ?Plan?), each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of S

Form of Non-Statutory Stock Option Agreement – Under the 2021 Inducement Equity Incentive Plan (Incorporated by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2022.)

Exhibit 10.16 SAVARA INC. NON-STATUTORY STOCK OPTION AGREEMENT (INDUCEMENT AWARD) THIS NON-STATUTORY STOCK OPTION GRANT AGREEMENT (this ?Agreement?), effective as of [?] (the ?Grant Date?), is entered into by and between Savara Inc., a Delaware corporation (the ?Company?), and [?] (the ?Grantee?). 1. Grant of Option. The Company hereby grants to the Grantee a non-statutory stock option (the ?Optio

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0

Savara Inc. 2021 Inducement Equity Incentive Plan, as amended

Exhibit 4.2 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended September 1, 2021) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employment with the Company or any Parent or Subsidiary of the Company.

List of Subsidiaries

Exhibit 21.1 Savara Inc. List of Subsidiaries Name Ownership % Aravas Inc. 100% Savara ApS 100% Drugrecure A/S 100% Pharmaorigin A/S 100% Savara Australia Pty Limited 100% Aires Pharmaceuticals, Inc. 100% SD Pharmaceuticals, Inc. 100%

SVRA / Savara Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

SVRA / Savara Inc / CAXTON CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

SVRA / Savara Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - SAVARA INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2022 SAVARA INC.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2022 SAVARA INC.

© Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by

Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2022 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.

Savara Inc. 6836 Bee Cave Road Building III, Suite 200 Austin, TX 78746 July 14, 2021

Savara Inc. 6836 Bee Cave Road Building III, Suite 200 Austin, TX 78746 July 14, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Savara Inc. Registration Statement on Form S-3 Filed July 6, 2021 File No. 333-257709 Acceleration Request Requested Date: July 16, 2021 Requested Time: 4:00 p.m. (Eastern time), or as soon t

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 2, 2021 SAVARA INC.

Composite Amended and Restated Certificate of Incorporation, as amended, of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form S-3 filed on July 6, 2021.)

Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows. 1.

Sales Agreement, dated July 6, 2021, between the Registrant and Evercore Group L.L.C. (Incorporated by reference to Exhibit 1.2 of the Registrant’s Registration Statement on Form S-3 filed on July 6, 2021.)

Exhibit 1.2 Execution Version SAVARA INC. SHARES OF COMMON STOCK (PAR VALUE $0.001 PER SHARE) SALES AGREEMENT July 6, 2021 Evercore Group L.L.C. 55 East 52nd Street New York, NY 10055 Ladies and Gentlemen: SAVARA INC., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with EVERCORE GROUP L.L.C. (the ?Agent?) as follows: 1. Issuance and Sale of Shares. The Company ag

Savara Inc. 2021 Inducement Equity Incentive Plan

Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of

As filed with the Securities and Exchange Commission on July 6, 2021

As filed with the Securities and Exchange Commission on July 6, 2021 Registration No.

Form of Senior Indenture

Exhibit 4.4 SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1. Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1. Designation and Terms of Securities 5 Section 2.2. Form of Securities and Trustee?s Certificate 7 Section 2.

As filed with the Securities and Exchange Commission on July 6, 2021

Table of Contents As filed with the Securities and Exchange Commission on July 6, 2021 Registration No.

Form of Subordinated Indenture

Exhibit 4.5 SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities 5 Section 2.2 Form of Securities and Trustee?s Certificate 7 Section

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2021 SAVARA INC.

Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation

Exhibit 3.1 SAVARA INC. CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify that: 1. The name of the Corporation is Savara Inc. 2. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the St

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2021 SAVARA INC.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2021 SAVARA INC.

Office Lease, dated June 3, 2021, between the Registrant and Overlook at Rob Roy Owner, LLC (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 4, 2021.)

Exhibit 10.1 BASIC LEASE INFORMATION The following Basic Information is incorporated into and made a part of this lease. Each reference in this lease to any of the Basic Lease Information shall mean the respective information set forth below and shall be construed to incorporate all of the terms provided under the particular lease paragraph(s) pertaining to such information. In the event of a conf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc

Work Order under Master Services Agreement by and between Savara Inc. and Parexel International (IRL) Limited, effective January 6, 2021 (Incorporated by reference to Exhibit 10.5 of the Registrant's Quarterly Report on Form 10-Q filed on May 13, 2021.)

Exhibit 10.5 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential. [***] indicates where such information has been omitted. Parexel Project # [***] WORK ORDER This Work Order #1 (this ?Work Order?) is by and between Savara Inc. (?Client?)

Master Services Agreement by and between Savara Inc. and Parexel International (IRL) Limited, effective January 6, 2021 (Incorporated by reference to Exhibit 10.4 of the Registrant's Quarterly Report on Form 10-Q filed on May 13, 2021.)

Exhibit 10.4 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential. [***] indicates where such information has been omitted. MASTER SERVICES AGREEMENT This Master Services Agreement (this ?Agreement?) is effective as of January 6, 2021 (the

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the

- PRE 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the

Fourth Amendment, dated March 30, 2021, to Loan and Security Agreement, dated April 28, 2017, as amended on October 31, 2017, December 4, 2018 and January 31, 2021, between the Registrant, Aravas Inc. and Silicon Valley Bank (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on April 1, 2021.)

Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 30, 2021, by and among SILICON VALLEY BANK, a California corporation (?Bank?), SAVARA INC. f/k/a MAST THERAPEUTICS, INC., a Delaware corporation (?Parent?), and ARAVAS INC. f/k/a SAVARA INC., a Delaware corporation (each a ?Co-Borrower? an

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2021 SAVARA INC.

Savara Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) March 15, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __ )* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) (CUSIP Num

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities E

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2021 SAVARA INC.

Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,”

EX-99.1 Savara Corporate Presentation (NASDAQ: SVRA) March 2021 Exhibit 99.1 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Suc

45,785,828 Shares of Common Stock Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225994 PROSPECTUS SUPPLEMENT (To Prospectus dated July 13, 2018) 45,785,828 Shares of Common Stock Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock We are offering 45,785,828 shares of our common stock, $0.001 par value per share, at a purchase price of $1.45 per share in this offering. We are also offering to

Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on March 11, 2021.)

Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [?] Number of Shares: [?] (subject to adjustment) Original Issue Date: March [?], 2021 Savara Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its permitted registered assigns (the ?Hold

Underwriting Agreement, dated March 11, 2021, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein

Exhibit 1.1 45,785,828 Shares of Common Stock and Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT March 11, 2021 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladies an

Form of Warrant Repurchase Agreement (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on March 11, 2021.)

Exhibit 10.1 FORM OF WARRANT REPURCHASE AGREEMENT THIS WARRANT REPURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of March [?], 2021 by and among Savara Inc., a Delaware corporation (the ?Company?), and the entities listed on Exhibit A (each, a ?Seller?). WHEREAS, each Seller owns a warrant dated December 24, 2019 (the ?Warrant?) to purchase the number of shares of the Company?s Co

SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AUSTIN, TX – March 11, 2021 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offere

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2021 SAVARA INC.

SUBJECT TO COMPLETION, DATED MARCH 10, 2021

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225994 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

Executive Employment Agreement, dated March 9, 2021, between Savara Inc. and Badrul Chowdhury

Exhibit 10.1 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of March 9, 2021 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and Badrul Chowdhury (?Executive?). WHEREAS, Executive is currently employed by the Company as the Company?s Chief Medical Officer pursuant to the terms of an offer letter agreement dated

Form of Incentive Stock Option Grant Agreement – Exempt Employees, in accordance with Danish employment law, under the 2015 Omnibus Incentive Plan.

Exhibit 10.9 Savara Inc. 2015 Omnibus Incentive Plan Incentive Stock Option Grant Agreement ? Exempt Employees THIS INCENTIVE STOCK OPTION GRANT AGREEMENT (this ?Agreement?), effective as of [?] (the ?Grant Date?), is entered into by and between Savara Inc., a Delaware corporation (the ?Company?), and [?] (the ?Participant?). 1.Grant of Option. The Company hereby grants to the Participant [NUMBER]

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2021 SAVARA INC.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) (CUS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) (CUS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 15, 2021 SAVARA INC.

Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,”

EX-99.1 Savara Corporate Presentation (NASDAQ: SVRA) January 2021 Exhibit 99.1 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. S

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2020 SAVARA INC.

Amended and Restated Executive Employment Agreement, dated December 8, 2020, between Savara Inc. and Matthew Pauls (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on December 10, 2020.)

EX-10.1 2 d38434dex101.htm EX-10.1 Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of December 8, 2020 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Matthew Pauls (“Executive”). This Agreement amends and restates and supersedes in its entirety the Exec

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2020 SAVARA INC.

SAVARA PROVIDES PIPELINE AND BUSINESS UPDATE Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operat

Exhibit 99.1 SAVARA PROVIDES PIPELINE AND BUSINESS UPDATE Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses to Align with Streamlined Development Programs Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex i

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara

SAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer

EX-99.1 3 d34590dex991.htm EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer AUSTIN, TX – Sept. 11, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CE

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2020 SAVARA INC.

Executive Employment Agreement, dated September 11, 2020, between Savara Inc. and Matthew Pauls

EX-10.1 2 d34590dex101.htm EX-10.1 Exhibit 10.1 Execution Version SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of September 11, 2020 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Matthew Pauls (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chairman and Interim CEO pursu

SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q

EX-99.1 2 d26703dex991.htm EX-99.1 Exhibit 99.1 SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q1 2021 AUSTIN, TX – August 6, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2020 SAVARA INC.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.

Savara Inc. Amended and Restated 2015 Omnibus Incentive Plan, as amended (Incorporated by reference to Appendix A of the Registrant’s Proxy Statement filed on April 19, 2022.)

EX-10.1 2 d830249dex101.htm EX-10.1 Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED 2015 OMNIBUS INCENTIVE PLAN (as amended by the Board on March 10, 2020, and approved by the stockholders on May 29, 2020) Savara Inc., a Delaware corporation (f/k/a Mast Therapeutics, Inc., the “Company”), hereby establishes the amended and restated 2015 Omnibus Incentive Plan (the “Plan”), effective as of the Effect

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2020 SAVARA INC.

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc

SAVARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP

EX-99.1 2 d895900dex991.htm EX-99.1 Exhibit 99.1 SAVARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP AUSTIN, TX – May 7, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2020 and provided a

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2020 SAVARA INC.

License and Collaboration Agreement between Savara Inc. and Grifols, S.A, dated January 7, 2020, as amended by Amendment No. 1, dated February 18, 2020, and Amendment No. 2, dated March 31, 2020 (Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed on May 7, 2020.)

Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. LICENSE AND COLLABORATION AGREEMENT This License and Collaboration Agreement (the “Agreement”) is entered into as of January 7, 2020 (the “Effective Date”) by a

47,927,176 Shares of Common Stock

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-237734 PROSPECTUS 47,927,176 Shares of Common Stock This prospectus relates to the resale from time to time of up to 47,927,176 shares of common stock of Savara Inc. by the selling stockholders listed on page 6, including their transferees, pledgees or donees or their respective successors, which consists of 9,569,430 ou

-

CORRESP April 27, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Tim Buchmiller Re: Savara Inc. Registration Statement on Form S-3 File No. 333-237734 Acceleration Request Requested Date: April 29, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule

SVRA / Savara Inc S-8 - - S-8

S-8 As filed with the Securities and Exchange Commission on April 17, 2020 Registration No.

SVRA / Savara Inc S-3 - - S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on April 17, 2020 Registration No.

Restricted Stock Unit Agreement (Inducement Grant) between Badrul Chowdhury and Savara Inc. dated November 26, 2019.

EX-4.2 Exhibit 4.2 SAVARA INC. RESTRICTED STOCK UNIT AGREEMENT (INDUCEMENT AWARD) NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Awardee has been granted an award of Restricted Stock Units (the “Award”) pursuant to this Agreement, each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of Savara Inc. (the “Company”), as follows: Awardee: Badrul

SVRA / Savara Inc DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission

Schedule 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2020 SAVARA INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 12, 2020 SAVARA INC.

Restricted Stock Unit Agreement (Inducement Grant) between Badrul Chowdhury and Savara Inc. dated November 26, 2019.

EX-10.36 3 svra-ex103615.htm EX-10.36 Exhibit 10.36 SAVARA INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Awardee has been granted an award of Restricted Stock Units (the “Award”) pursuant to the Savara Inc. 2015 Omnibus Incentive Plan (the “Plan”), each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of Savara Inc. (the “Company”), as f

Non-statutory Stock Option Agreement (Inducement Award) between Badrul Chowdhury and Savara Inc. dated November 26, 2019 (Incorporated by reference to Exhibit 10.37 to the Registrant’s Annual Report on Form 10-K filed on March 12, 2020.)

EXHIBIT 10.37 SAVARA INC. NON-STATUTORY STOCK OPTION AGREEMENT (INDUCEMENT AWARD) THIS NON-STATUTORY STOCK OPTION GRANT AGREEMENT (this “Agreement”), effective as of November 26, 2019 (the “Grant Date”), is entered into by and between Savara Inc., a Delaware corporation (the “Company”), and Badrul Chowdhury (the “Grantee”). 1.Grant of Option. The Company hereby grants to the Grantee a non-statutor

SAVARA REPORTS FOURTH QUARTER / YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex • Company

EX-99.1 2 d859106dex991.htm EX-99.1 Exhibit 99.1 SAVARA REPORTS FOURTH QUARTER / YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex • Company Planning an Additional Phase 3 Study of Molgradex for the Treatment of Autoimmune Pulmonary Alveolar

Description of Registered Securities (Incorporated by reference to Exhibit 4.25 to the Registrant’s Annual Report on Form 10-K filed on March 12, 2020.)

Exhibit 4.25 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description of registered securities of Savara Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our amended and res

Executive Employment Agreement, dated September 6, 2019, between Savara Inc. and Badrul Chowdhury, Chief Medical Officer.

Exhibit 10.39 Badrul Chowdhury, MD, PhD Transmitted via email to: [email protected] Dear Badrul, Savara Inc. (“Savara’’ or “Company’’) is extremely pleased to extend to you an offer of employment with our Company as Chief Medical Officer. This offer letter and the terms contained herein supersede all other communications verbal or written. Subject to your acceptance of the terms herein, we would e

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex

SVRA / Savara Inc / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

SVRA / Savara Inc / Altium Capital Management Lp - AMENDMENT TO FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Savara Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

SVRA / Savara Inc / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SAVARA INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Second Amendment to Warrant to Purchase Common Stock dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Life Science Loans II, LLC on April 28, 2017 (as amended by that certain Amendment to Warrant to Purchase Common Stock dated as of June 26, 2017) (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.)

EX-4.1 Exhibit 4.1 SECOND AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Second Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between LIFE SCIENCE LOANS II, LLC (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Holder that certain Warrant to Purchase Common Stock dated

Third Amendment, dated January 31, 2020, to Loan and Security Agreement, dated April 28, 2017, as amended on October 31, 2017 and December 4, 2018, among the Registrant, Aravas Inc. and Silicon Valley Bank (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.)

EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of January 31, 2020, by and among SILICON VALLEY BANK, a California corporation (“Bank”), SAVARA INC. f/k/a MAST THERAPEUTICS, INC., a Delaware corporation (“Parent”), and ARAVAS INC. f/k/a SAVARA INC., a Delaware corporation (each a “Co-Borr

Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Silicon Valley Bank on June 26, 2017 (Incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.)

EX-4.4 Exhibit 4.4 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between SVB FINANCIAL GROUP (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Silicon Valley Bank (“Bank”) that certain Warrant to Purchase Common

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2020 SAVARA INC.

Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Life Science Loans II, LLC on December 4, 2018 (Incorporated by reference to Exhibit 4.5 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.)

EX-4.5 Exhibit 4.5 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between LIFE SCIENCE LOANS II, LLC (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Holder that certain Warrant to Purchase Common Stock dated De

Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Silicon Valley Bank on December 4, 2018 (Incorporated by reference to Exhibit 4.6 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.)

EX-4.6 Exhibit 4.6 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between SVB FINANCIAL GROUP (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Silicon Valley Bank (“Bank”) that certain Warrant to Purchase Common

Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Life Science Loans II, LLC on June 26, 2017 (Incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.)

EX-4.3 Exhibit 4.3 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between LIFE SCIENCE LOANS II, LLC (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Holder that certain Warrant to Purchase Common Stock dated Ju

Second Amendment to Warrant to Purchase Common Stock dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Silicon Valley Bank on April 28, 2017 (as amended by that certain Amendment to Warrant to Purchase Common Stock dated as of June 26, 2017) (Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.)

EX-4.2 Exhibit 4.2 SECOND AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Second Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between SVB FINANCIAL GROUP (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Silicon Valley Bank (“Bank”) that certain Warrant to Purchase Comm

SVRA / Savara Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Savara Inc. (Name of Issuer) Common Stock, Par Value $.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 20, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D

EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) jo

SVRA / Savara Inc / Bain Capital Life Sciences Fund II, L.P. - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.

SAVARA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR MOLGRADEX FOR THE TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (aPAP)

EX-99.1 Exhibit 99.1 SAVARA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR MOLGRADEX FOR THE TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (aPAP) AUSTIN, TX – Dec. 30, 2019 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombi

Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 23, 2019 SAVARA INC.